Stocks · News reference
Filed: 2026-08-26 AccNo: 0001193125-26-365975 Size: 406 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug
Read original at benzingaGuggenheim analyst Brad Canino maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $165 to $175.
Read original at benzingaCitizens analyst Silvan Turkcan reiterates Celcuity (NASDAQ:CELC) with a Market Outperform and maintains $177 price target.
Read original at benzinga